Improving interpretability of individual Diabetes Symptom Checklist-Revised (DSC-R) scores: the role of patient characteristics

Thomas H Wieringa,1 Maartje de Wit,1 Jos W R Twisk,2 Frank J Snoek1

ABSTRACT

Introduction The Diabetes Symptom Checklist-Revised (DSC-R) is a well-validated patient-reported outcome designed to assess symptom burden in persons with type 2 diabetes mellitus (T2DM) across eight domains. The DSC-R has so far primarily been used in research settings. With the aim to make the DSC-R applicable in clinical practice by improving its interpretability, we sought to identify patient characteristics associated with DSC-R (domain) scores as a first initiative toward reference values.

Research design and methods We used baseline data from two large observational studies to select patient characteristics significantly associated with DSC-R domain and total scores. Multivariable Tobit analyses with the backward procedure per (domain) score were performed.

Results Data from 1531 participants with T2DM were included. On a 0–100 scale, the median DSC-R total score was 15.88 (7.06–29.41), with domain scores ranging from 5.00 (0.00–22.50) (pain) to 35.00 (10.00–60.00) (fatigue). Low well-being status was most profoundly associated with higher scores across all domains. Persons with one or more complication, as well as one or more symptomatic hypoglycemic episode during the past 3 months, scored higher on (almost) all domains and the total scale.

Conclusions Complications, symptomatic hypoglycemia, and low well-being are important characteristics to take into account when using the DSC-R in individual patients. Further validation of our findings is warranted in diverse patient populations.

BACKGROUND

The Diabetes Symptom Checklist (DSC) was developed by Groothuis et al.1 25 years ago in the context of the Hoorn study to reliably capture the experience of diabetes-related symptom distress of persons with type 2 diabetes mellitus (T2DM) and changes therein as a result of medical treatment.1 Based on research data, the DSC was revised in two ways: (1) for the sake of simplicity and to avoid confusion, the frequency scale was replaced by a dichotomous yes/no response for the presence or absence of each symptom; and (2) the scaling was changed from a 4-point to a 5-point Likert scale to enhance variability,2 resulting in the DSC-Revised (DSC-R).3 The DSC-R consists of 34 items grouped into 8 symptom domains: fatigue, cognitive symptoms, pain, sensitivity symptoms, cardiological symptoms, ophthalmic symptoms, hypoglycemia, and hyperglycemia. It asks about the burden of diabetes symptoms experienced during the past month. The DSC-R has good psychometric properties3 and has been validated in a multitude of languages and used primarily as patient-reported outcome (PRO) in clinical trials.

Significance of this study

What is already known about this subject?

► The Diabetes Symptom Checklist-Revised (DSC-R) is a well-validated, widely used patient-reported outcome designed to assess symptom burden in persons with type 2 diabetes mellitus across eight domains.

► The DSC-R has so far primarily been used in research settings and may have clinical utility.

► Individual use of DSC-R scores in routine care requires good interpretability, based on reference values.

What are the new findings?

► Diabetes complications, symptomatic hypoglycemia, and low well-being are characteristics to take into account when using the DSC-R in individual patients.

How might these results change the focus of research or clinical practice?

► The relevant associations presented and their directions can help improve the interpretability of DCS-R domain and total scores.

► Especially mood status should be taken into account.

► The associations found may be a first step for future research to focus on creating reference values or weights for different groups, as well as establishing clinically meaningful differences in diabetes symptom burden.
When aiming to use the DSC-R as PRO in clinical practice, reference values are an important feature to consider. Interpretability is a key issue for using the DSC-R in clinical practice, that is, in individual patients, and can be defined as ‘the degree to which one can assign qualitative meaning to an instrument’s quantitative scores or change in scores’, or in other words ‘the degree to which it is clear what the scores or change scores mean’. Interpretability is not a measurement property, like validity and reliability, because it does not refer to the quality of an instrument. Rather, it refers to what the scores on an instrument mean and is a prerequisite for any instrument to be applicable in clinical practice. In this context it is essential to have reference values, differentiated according to relevant patient characteristics. For example, previous research has shown that symptom report is partly explained by negative affect. In the Hoorn screening study, negative mood was found to significantly amplify diabetes symptom burden, as measured by the DSC-R. In other words, when interpreting DSC-R scores on an individual basis, we need to be cognizant of patient-related factors that may influence symptom reporting, such as gender, age, and complication status, and these associations may be generic or domain-specific. For this purpose we need to assess which patient characteristics are associated with DCS-R domain and total scores.

The current study aims to improve the clinical usefulness of the DSC-R through establishing which patient characteristics are associated with DSC-R (domain) scores.

### METHODS

Baseline data were used from the SPIRIT (Study of the Psychological Impact in Real care of Initiating insulin glargine Treatment) and the ESPRIT (Effect Study on Patient-Reported outcomes in Insulin glargine Treatment) studies and were merged. The SPIRIT data set includes data from 1021 persons with T2DM prior to switching from oral glucose-lowering agents to a long-acting insulin (glargine-100). The ESPRIT data set includes 510 persons with T2DM prior to switching from any long-acting insulin to insulin glargine-100. Details of the SPIRIT and the ESPRIT study are reported elsewhere.

In both SPIRIT and ESPRIT, hemoglobin A1c (HbA1c) was retrieved from the medical chart and demographic and clinical data were self-reported. The DSC-R domain and total scores were standardised to 0–100, with higher scores representing better emotional well-being pertaining to the past 2 weeks. Scores were divided into categories: a score ≤28 is indicative of depression, and a score >28 and ≤50 is indicative of low mood, and a score higher than 50 is indicative of normal well-being.

### Analyses

Multiple imputation on the item level was performed, in which imputation models were created per DSC-R domain score. These imputation models contained items of the domain, as well as the original (non-dichotomized) patient characteristics potentially associated with the DSC-R (domain) scores. Multiple imputation using five imputations, which results in five imputed data sets, was performed in SPSS V.22.

Both DSC-R domain and total scores were standardized to 0–100 scores, with higher scores representing higher symptom burden. Because of the large numbers of zero-scores for the DSC-R domains and total scale, Tobit regression analyses were performed using Stata V.15. All analyses were repeated in five different data sets and consisted of three steps: (1) multivariable Tobit

### Table 1 Baseline data of the study population (n=1531)*†

| Gender | 750 (49.20%) |
| Age   | 61.37 (10.90) |
| Low   | 699 (53.60%) |
| Middle| 467 (35.80%) |
| High  | 138 (10.60%) |
| Diabetes duration (years) | 7.00 (4.00–12.00) |
| Complications | |
| 0 | 881 (62.70%) |
| ≥1 | 523 (37.30%) |
| Comorbidities | |
| 0 | 1367 (89.30%) |
| ≥1 | 164 (10.70%) |
| HbA1c mmol/mol | 69.32 (16.45) |
| % | 8.49 (1.51) |
| Body mass index | 30.53 (6.27) |
| Treatment | |
| Oral agents | 1021 (66.70%) |
| Insulin | 510 (33.30%) |
| Symptomatic hypoglycemia during the past 3 months (self-report) | |
| 0 episode | 584 (48.90%) |
| ≥1 episode | 610 (51.10%) |
| Severe hypoglycemia during the past 3 months (self-report) | |
| 0 episode | 1191 (94.30%) |
| ≥1 episode | 72 (5.70%) |
| WHO-5 score (well-being) | 60.00 (40.00–76.00) |

*Based on non-imputed data. †For categorical variables: frequencies (valid percentages); for normally distributed continuous variables: median (25th–75th percentile); for skewed distributed continuous variables: median (25th–75th percentile). HbA1c, hemoglobin A1c.
analyses using a backward procedure to select the characteristics significantly associated with the domain scores and total DSC-R score; (2) final models were created only for those variables significantly associated with the outcome of interest in at least three imputed data sets; and (3) based on the final models, Rubin’s rule was used to obtain pooled regression coefficients and 95% CIs. A p value of 0.05 was used as threshold for a statistically significant association.

Patient characteristics potentially associated with DSC-R (domain) scores were dichotomized in order to enhance interpretability and clinical applicability based on medians and guidelines. The following were the variables found to be associated with symptom burden in previous studies and were included as independent variables in the first model for the backward procedure:

- Sociodemographics: gender, age (<70 years vs ≥70 years), and level of education (low, middle, high).
- Clinical characteristics: diabetes duration (<10 years vs ≥10 years), complication status (0 vs ≥1), comorbidity (0 vs ≥1), glycemic control (HbA1c ≤64.00 mmol/mol (≤8.00%)) vs >64.00 mmol/mol (>8.00%), body mass index (BMI) (non-obese (<30) vs obese (≥30)), treatment (using oral agents vs using insulin), self-reported symptomatic hypoglycemia (0 vs ≥1 episode in the past 3 months), and self-reported severe hypoglycemia (0 vs ≥1 episode in the past 3 months).
- Psychological well-being status (normal well-being, low mood, likely depression).

### RESULTS

The total data set included 1531 patients with T2DM, of whom 49.20% were female and with a mean diabetes duration of 7 years (table 1).

The median and IQR (25th–75th percentile) for the DSC-R domain and total scores of the study population are presented in table 2. The median DSC-R total score was 15.88 (7.06–29.41), and the median domain scores ranged from 5.00 (0.00–22.50) (pain) to 35.00 (10.00–60.00) (fatigue).

### DISCUSSION

Based on combined data from two large observational studies including insulin-naïve and insulin-treated patients with T2DM, we investigated which patient characteristics are associated with patient-reported diabetes symptom burden. Responses on the DSC-R showed a wide variation in occurrence and degree of troublesomeness, underscoring the need to better understand individual differences, taking patient characteristics into account.

Fatigue is reported as the most common and most burdensome symptom of diabetes. Indeed, fatigue is known to be prevalent in persons with type 1 and type 2 diabetes. Fatigue was most pronounced in patients with lower well-being status. Persons with low mood score around 33 points (on a 0–100 scale) higher compared with persons with normal well-being, while those likely depressed score approximately 46 points as higher relative to normal well-being. Low mood and likely depression do not only impact on fatigue, but amplify scores on all other domains of the DSC-R, in particular cognitive symptoms and hypoglycemic and hyperglycemic symptoms. Our findings are consistent with previous studies that found an association between psychological well-being and subjective symptom report. Several plausible explanations for this association have been suggested, but the causation remains unclear. Painful symptoms may induce or further increase depressed mood, while depression can amplify reported symptom burden, possibly due to a focus on symptoms and selective recall of negative events. Furthermore, negative affect may induce hypervigilance, which leads to an increase in ‘scanning’ of the body, that is, attention directed to the body, resulting in more somatic symptoms being detected. This mechanism may also drive the association between self-reported symptomatic hypoglycemia and DSC-R scores. Future research should aim to clarify this relationship by using continuous glucose monitoring for objective recording of hypoglycemic episodes.

### Table 2

| Table 2 | Median and IQR for DSC-R total scores and domain scores (n=1531)* |
|---------|---------------------------------------------------------------|
| Total DSC-R | 15.88 (7.06–29.41) |
| Fatigue | 35.00 (10.00–60.00) |
| Cognitive symptoms | 15.00 (0.00–40.00) |
| Pain | 5.00 (0.00–22.50) |
| Sensitivity symptoms | 6.67 (0.00–26.67) |
| Cardiological symptoms | 10.00 (0.00–25.00) |
| Ophthalmic symptoms | 8.00 (0.00–24.00) |
| Hypoglycemias | 6.67 (0.00–26.67) |
| Hyperglycemia | 20.00 (5.00–40.00) |

*Based on non-imputed (original) data. DSC-R, Diabetes Symptom Checklist-Revised.
Table 3  Regression coefficients of patient characteristics significantly associated with DSC-R (domain) scores: results from multivariable Tobit analyses*

|                      | Total Fatigue | Cognitive symptoms | Pain | Sensitivity symptoms | Cardiological symptoms | Ophthalmic symptoms | Hypoglycemia | Hyperglycemia |
|----------------------|---------------|--------------------|------|----------------------|------------------------|--------------------|--------------|--------------|
| **Gender†**          |               |                    |      |                      |                        |                    |              |              |
| Gender†              | 4.96          | (1.94 to 7.98)     |      |                      |                        |                    |              |              |
| Age                  | 4.88          | (0.53 to 9.23)     |      |                      |                        |                    |              |              |
| **Education**        |               |                    |      |                      |                        |                    |              |              |
| Diabetes duration    | −1.49         | (−3.00 to 0.02)    |      | −4.10                | (−6.96 to −1.24)       |                    |              | −10.77       |
|                      | −2.95         | (−6.09 to 0.19)    |      |                      |                        |                    | −15.26       |
| Complications        | 3.52          | (1.91 to 5.13)     |      | 3.53                 | (0.75 to 6.31)         |                    |              |              |
|                      | 4.21          | (0.00 to 8.42)     |      | 8.75                 | (5.01 to 12.49)        |                    |              |              |
|                      | 9.22          | (5.87 to 12.57)    |      | 5.63                 | (2.32 to 8.94)         |                    |              |              |
|                      | 4.92          | (1.24 to 8.60)     |      |                      |                        |                    |              |              |
| **Comorbidity**      | 2.29          | (0.09 to 4.49)     |      |                      |                        |                    | 11.09        |
|                      | 5.11          | (−0.06 to 10.28)   |      |                      |                        |                    |              |              |
| **HbA1c**            |               |                    |      |                      |                        |                    | 5.74         |
|                      | 5.65          | (1.91 to 9.39)     |      |                      |                        |                    |              |              |
|                      | 6.67          | (3.48 to 9.86)     |      |                      |                        |                    |              |              |
| **BMI**              | 2.57          | (1.18 to 3.96)     |      | 5.47                 | (2.63 to 8.31)         |                    |              |              |
|                      | 5.65          | (1.91 to 9.39)     |      |                      |                        |                    |              |              |
|                      | 6.67          | (3.48 to 9.86)     |      |                      |                        |                    |              |              |
| **Treatment‡**       |               |                    |      |                      |                        |                    | 4.61         |
|                      |               |                    |      |                      |                        |                    | (0.63 to 8.59)|              |
| **Symptomatic hypoglycemia** | 5.74    | (4.25 to 7.23)     |      | 11.42                | (8.83 to 14.01)        |                    |              |              |
|                      | 7.43          | (4.22 to 10.64)    |      | 9.36                 | (5.54 to 13.18)        |                    |              |              |
|                      | 8.70          | (5.52 to 11.88)    |      | 6.32                 | (2.64 to 10.00)        |                    |              |              |
|                      | 6.90          | (3.51 to 10.29)    |      | 12.98                | (8.65 to 17.31)        |                    |              |              |
| **Severe hypoglycemia** | 3.92    | (0.76 to 7.08)     |      |                      |                        |                    | 6.98         |
|                      |               |                    |      |                      |                        |                    | (0.20 to 13.76)|              |
| **Low mood§**        | 11.09         | (9.44 to 12.74)    |      | 33.03                | (29.85 to 36.21)       |                    |              |              |
|                      | 20.56         | (16.93 to 24.19)   |      | 8.38                 | (3.87 to 12.89)        |                    |              |              |
|                      | 9.09          | (5.39 to 12.79)    |      | 10.67                | (6.63 to 14.51)        |                    |              |              |
|                      | 6.29          | (2.25 to 10.33)    |      | 20.28                | (15.42 to 25.14)       |                    |              |              |
| **Likely depression¶** | 19.56 | (17.54 to 21.58)   |      | 46.44                | (42.72 to 50.16)       |                    |              |              |
|                      | 33.67         | (27.10 to 40.24)   |      |                      |                        |                    |              |              |

*The group with the lowest value(s) is used as reference (see the Methods section for the categories per patient characteristic).
†Male is coded as 0, female as 1.
‡Using oral agents is coded as 0, using insulin as 1.
§Normal well-being is coded as 0, low mood as 1.
¶Normal well-being is coded as 0, likely depression as 1.
BMI, body mass index; DSC-R, Diabetes Symptom Checklist-Revised; HbA1c, hemoglobin A1c.
It is unclear why patients with a diabetes duration of \( \geq 10 \) years report lower fatigue, cognitive, hyperglycemia, and total symptom burden relative to those with shorter disease duration. Response shift or adaptation may play a role in this.\(^2\) Possibly, people suffering longer from diabetes may be less emotionally burdened compared with those recently diagnosed, resulting in lower negative affectivity in the latter group. Further research into the role of age and diabetes duration as a determinant of symptom distress is warranted.

Besides symptomatic hypoglycemia and diabetes duration, important clinical characteristics to take into account seem to be complication status and BMI. Interestingly, treatment regimen and glycemic control seem to differentiate less in terms of symptom burden. The strength of the association is probably dependent on the level of glycemic control, where one could expect a stronger impact on symptom burden in patients in poorer control versus those in better control.\(^22\)

The significant associations and their regression coefficients presented here need further testing, but should help clinicians to interpret DSC-R domain and total scores, taking relevant patient characteristic into account. As to the clinical application of our findings, it is advised to focus on (changes in) DSC-R scores at the domain level.\(^2\) The total DSC-R score is informative, but we should be aware that no difference in total DSC-R score over time does not exclude the possibility that there actually might have been changes within domains (eg, one domain score worsened while another improved). Further research into the minimal clinically important difference (MCID) for the DSC-R is warranted for interpretation of changes in scores, building on a previous study providing preliminary results.\(^3\) The MCID is the smallest benefit of value to persons with T2DM capturing both the magnitude of the improvement and the value persons place on the change.\(^30\)

**Strengths and limitations**

The data were derived from a large sample of persons with T2DM from both primary and secondary care settings at different stages of (insulin) therapy across different regions of the Netherlands,\(^7\)\(^8\) which favors the external validity (ie, generalizability) of our findings. We were unable to study the role of different kinds of complications and comorbidities in symptom burden because of the relatively low prevalence of complications and comorbidities. This is a limitation of the current study as symptoms associated with T2DM may be directly related to complications and comorbidities. In this way, symptom burden domains are likely to be affected differently, depending on the seriousness and impact of complications and comorbidities. Furthermore, the relevant associations were found in a sample of mainly Caucasian patients with T2DM. Future research should replicate our study in diverse patient populations to define and further validate reference values. Here, studying the role of different kinds of complications and comorbidities will be of value. The relatively large number of missing data is a potential weakness of observational studies and was confirmed in the current study. However, multiple imputation can be viewed as the most robust way of dealing with missing data.\(^31\)

**CONCLUSIONS**

The relevant associations presented and their directions can help improve the interpretability of the DCS-R domain and total scores. Future research may focus on creating reference values or weights for different patient groups, as well as establishing clinically meaningful differences in diabetes symptom burden.

**Acknowledgements** We would like to thank the Amsterdam Public Health research institute for providing a travel grant through which THW visited the Mayo Clinic in Rochester (Minnesota, USA). We would also like to thank the Knowledge and Evaluation Research Unit of the Mayo Clinic for sharing their ideas and giving suggestions regarding improvement of the DSC-R. We would like to thank Marcel Adriaanse for his time and effort searching data sets in which the DSC-R is included.

**Contributors** THW, MW, and FJS designed the study. THW performed the data analyses and drafted the manuscript. JWRT supported the data analyses. MW, JWRt, and FJS provided feedback on the manuscript (drafts), which was processed by THW. All authors read and approved the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** The data reported here were collected from previous studies conducted with a grant from Sanofi received by the institution (Amsterdam UMC, location VU University Medical Center).

**Patient consent for publication** Not required.

**Ethics approval** The current study is based on two existing data sets. Both studies were, in view of their observational and non-invasive nature, not subject to the Dutch Medical Research Involving Human Subjects Act.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** The de-identified participant data that underlie the results reported in this article are available from m.dewit@amsterdamumc.nl upon reasonable request to researchers who provide a methodological sound proposal. Other documents that are available are study protocols and analytic codes. Proposals may be submitted up to 24 months following article publication.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Thomas H Wieringa http://orcid.org/0000-0001-8440-8844

**REFERENCES**

1. Grootenhuis PA, Snoek FJ, Heine RJ, et al. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. *Diabet Med* 1994;11:253–61.
2. De Vet HCW, Terwee CB, Mokkink LB, et al. Measurement in medicine: a practical guide. 1st edn. Cambridge: Cambridge University Press, 2011.
3. Arbuckle RA, Humphrey L, Vardeva K, et al. Psychometric evaluation of the Diabetes Symptom Checklist-Revisted (DSC-R)—a measure of symptom distress. *Value Health* 2009;12:1168–75.
4. Ciechanowski PS, Katon WJ, Russo JE, et al. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. *Gen Hosp Psychiatry* 2003;25:246–52.
5. Adrianiene MC, Dekker JM, Spijkerman AMW, et al. Diabetes-Related symptoms and negative mood in participants of a targeted...
population-screening program for type 2 diabetes: the Hoorn screening study. *Health Qual Life Outcomes* 2005;14:1501–9.

6. Ludman EJ, Katon W, Russo J, *et al*. Depression and diabetes symptom burden. *Gen Hosp Psychiatry* 2004;26:430–6.

7. Hajos TRS, Pouwer F, de Groot R, *et al*. Initiation of insulin Glargin in patients with type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. *Diabet Med* 2011;28:1096–102.

8. Hajos TRS, Pouwer F, de Groot R, *et al*. The longitudinal association between glycaemic control and health-related quality of life following insulin therapy optimisation in type 2 diabetes patients. A prospective observational study in secondary care. *Qual Life Res* 2012;21:1359–65.

9. World Health Organization. *Wellbeing measures in primary health care: the DepCare project: report on a who meeting*. Stockholm: WHO, 1998.

10. de Wit M, Pouwer F, Gemke RJBJ, *et al*. Validation of the WHO-5 well-being index in adolescents with type 1 diabetes. *Diabetes Care* 2007;30:2003–6.

11. Löwe B, Spitzer RL, Gräfe K, *et al*. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. *J Affect Disord* 2004;78:131–40.

12. Awata S, Bech P, Yoshida S, *et al*. Reliability and validity of the Japanese version of the world health Organization-Five well-being index in the context of detecting depression in diabetic patients. *Psychiatry Clin Neurosci* 2007;61:112–9.

13. Tobin J. Estimation of relationships for limited dependent variables. *Econometrica* 1958;26:24–36.

14. Twisk JWR. *Inleiding in de toegepaste biostatistiek*. 3rd edn. Houten: Bohn Stafleu van Loghum, 2014.

15. Van Binsbergen JJ, Langens FNM, Dapper ALM, *et al*. NHG-standaard obesitas. *Huisarts Wet* 2010;53:609–25.

16. Dutch Diabetes Federation. *NDF Zorgstandaard-diabetes type 2 volwassenen*. Amersfoort: Dutch Diabetes Federation, 2015.

17. Adriaanse MC, Pouwer F, Dekker JM, *et al*. Diabetes-Related symptom distress in association with glucose metabolism and comorbidity: the Hoorn study. *Diabetes Care* 2008;31:2268–70.

18. Lee E-H, Lee K-W, Song R, *et al*. Psychometric evaluation of the Korean version of the diabetes symptom Checklist-Revised (DSC-R) for patients with type 2 diabetes. *Health Qual Life Outcomes* 2014;12:77.

19. Wieringa TH, de Wit M, Twisk JWR, *et al*. Does hypoglycaemia affect the improvement in QOL after the transition to insulin in people with type 2 diabetes? *J Endocrinol Invest* 2018;41:249–58.

20. American Diabetes Association. *Complications*. Available: http://www.diabetes.org/living-with-diabetes/complications/?loc= symptoms [Accessed 15 Oct 2018].

21. Gulliford MC, Mahabir D. Relationship of health-related quality of life to symptom severity in diabetes mellitus: a study in Trinidad and Tobago. *J Clin Epidemiol* 1999;52:773–80.

22. Van der Does FE, De Neeling JN, Snoek FJ, *et al*. Symptoms and well-being in relation to glycemic control in type II diabetes. *Diabetes Care* 1996;19:204–10.

23. Jensen Øystein, Bernklev T, Jelsness-Jørgensen L-P. Fatigue in type 1 diabetes: a systematic review of observational studies. *Diabetes Res Clin Pract* 2017;123:63–74.

24. Singh R, Teel C, Sabus C, *et al*. Fatigue in type 2 diabetes: impact on quality of life and predictors. *PLoS One* 2016;11:e0165652.

25. Menting J, Nikolaus S, van der Veld WM, *et al*. Severe fatigue in type 1 diabetes: Exploring its course, predictors and relationship with HbA1c., in a prospective study. *Diabetes Res Clin Pract* 2016;121:127–34.

26. Von Korff M, Simon G. The relationship between pain and depression. *Br J Psychiatry* 1996;168:101–8.

27. Watson D, Pennebaker JW. Health complaints, stress, and distress: exploring the central role of negative affectivity. *Psychol Rev* 1989;96:234–54.

28. Teasdale JD. Negative thinking in depression: cause, effect, or reciprocal relationship? *Advances in Behaviour Research and Therapy* 1983;5:3–25.

29. Golub S. *Periods: from menarche to menopause*. 1st edn. Newbury Park: Sage Publications Inc, 1992.

30. McDaid EM, Jackson MC. Minimal clinically important difference: defining what really matters to patients. *JAMA* 2014;312:1342–3.

31. Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychol Methods* 2002;7:147–77.